8-K filing — IMMUCELL CORP /DE/ (ICCC)
Filed: 2026-10-13 AccNo: 0001437749-26-032465 Size: 178 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
ImmuCell shares are trading higher after the company reported preliminary Q3 sales of $8.0 million, a 46.0% increase compared to the three months ended September 30, 2025.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
ImmuCell Sees Q3 Sales $8.000M
ImmuCell (NASDAQ:ICCC) sees Q3 sales of $8.000 million.
ImmuCell Reports Q3 Preliminary Sales Of $8M, Up 46% YoY
ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity,